AI assistant
Vivimed Labs Ltd. Interim / Quarterly Report 2020
61575_rns_2020-06-03_70492f22-8ec7-4c95-bc83-05bde451e8e3.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Vivimed Labs Limited
Unaudited Consolidated Statement of Cash Flows for Six Months ended September 30, 2019
| Six Months Ended30 September 2019 | Six Months Ended30 September 2018Un-Audited | |
|---|---|---|
| Un-Audited | ||
| I. Cash flows from operating activities | ||
| Profit before tax | (201.63) | 574.74 |
| Adjustments to reconcile profit before tax to net cash flows: | ||
| Depreciation of tangible assets & Intangible assets | 338.48 | 354.47 |
| Other Aquisitons and adjustments | (445.56) | |
| Finance costs (including fair value change in financial instruments) | 276.93 | 392.13 |
| Operating profit before working capital changes | 413.78 | 875.78 |
| Changes in working capital: | ||
| Adjustment for (increase)/decrease in operating assets | ||
| Trade receivables | 784.68 | (1,021.01) |
| Inventories | 1,041.15 | 375.59 |
| Loans - current | (101.26) | (2,138.18) |
| Other assets | (123.81) | 30.85 |
| Adjustment for (increase)/decrease in operating liabilities | ||
| Trade payables | (407.95) | 699.62 |
| Other financial liabilities | (1,192.41) | (401.73) |
| Other liabilities | 90.04 | 1,436.67 |
| Provisions | (4.00) | 145.68 |
| Cash generated from operations | 500.22 | 3.27 |
| Income taxes paid | (137.71) | |
| Net cash generated from/(used in) operating activities | 362.51 | 3.27 |
| II. Cash flows from investing activities | ||
| Proceeds from sale/ (Purchase of) property, plant and equipment and | ||
| intangibles (including capital work in progress), net | (186.50) | 942.00 |
| Investments made during the year | (1.28) | (276.48) |
| Net cash used in investing activities | (187.78) | 665.52 |
| III. Cash flows from financing activities | ||
| Share issue proceeds | 9.36 | (1,003.27) |
| Movement in non-controling interest | ||
| Dividend paid & sale of subsidiaries | (81.82) | 150.34 |
| Proceeds from/(repayment of) long-term borrowings, net | (245.87) | 515.12 |
| Proceeds from/(repayment of) short term borrowings, net | 88.96 | (294.53) |
| Interest paid | (276.93) | (392.13) |
| Net cash provided by financing activities | (506.30) | (1,024.47) |
| Net increase in cash and cash equivalents $(I+II+III)$ | (331.57) | (355.69) |
| Cash and cash equivalents at the beginning of the year | ||
| 634.64 | 990.33 | |
| Cash and cash equivalents at the end of the year (refer note below) | 303.07 | 634.64 |
| Note: | ||
| Cash and cash equivalents comprise: | ||
| Cash on hand | 8.26 | 5.37 |
| Balances with banks: | ||
| - in current accounts | 605.20 | 629.27 |
| 613.47 | 634.64 | |
Place: Hyderabad Date: 14.11.2019
For WVIMED LARS LIMITED ハ SANTO H VARALWAR)MANAGING DIRECTOR
Vivimed Labs Limited
Unaudited Standalone Statement of Cash Flows for Six Months ended September 30, 2019
I. Cash flows from operating activities Profit before tax Adjustments to reconcile profit before tax 10 net cashflows: Depreciation of tangible assets Amortisation of intangible assets Others Finance income (including fair value change in financial instruments) Finance costs (including fair value change in financial instruments) Operating profit before working capital changes Changes in working capital: Adjustment for (increasej/decreasc ill operating assets Trade receivables Inventories Loans - current Other assets - current Adjustment for (increasej/decrcasc in operating liabilities Trade payables Other financial liabilities Other liabilities Provisions Cash generated from operations Income taxes paid Net cash generated from/(used in) operating activities 11. Cash flows from investing activities Proceeds from sale/ (Purchase on properly, plant and equipment and intangibles (including capital work in progress). net Investments made during the year Interest received (finance income) Net cash used in investing activities Ill. Cash flows from financing activities Share issue proceeds Dividend paid Proceeds from/trepayment 01) long-term borrowings, net Proceeds from/( repayment 0 f) short -term borrowings, net Interest paid Net cash provided by financing activities Net increase in cash and cash equivalents (1+11+111) Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the cud of the year (refer note below) Note: Cash and cash equivalents comprise: Cash 011 hand Balances with banks: - in current accounts Six Months Ended Six Months Ended 30-09-2019 30-09-2018 Un-Audited Un-Audited (38.54) 27.43 84.76 92.51 33.11 O.O[ 2 [ 1.29 228.16 l.':!J"/.':!JI. JIB.I.! 232.98 (810.90) 234.78 20.14 109.86 (423.76) (11866) (34.80) 657.97 (624.29) 129.64 15.12 665.80 (416) 7.68 68.34 627.78 (1490) 53.44 627.78 274.80 (56.31 ) (0.11) (0.01) 274.68 (56.31) 9.36 (47.05) - - ( [00.83) (275.80) 29.73 (39.96) (21 [.29) (223.67) (273.03) (586.47) 55.09 (15.01) - 91.79 55,09 76.78 2.35 3.68 52.74 73.10
Place: Hydernhad Dale: 14.11.2019
For VIVIM BS LIMITED (SANT~fY'?4AW ~~:)TOR
55.09 76.78
( Rupees millions)